Various phenotypes of short stature with heterozygous IGF-1 receptor (IGF1R) mutations

• Published in: Clinical Pediatric Endocrinology Vol. 31; no. 2; pp. 59 - 67
• Main Authors: Kawashima-Sonoyama, Yuki, Hotsubo, Tomoyuki, Hamajima, Takashi, Hamajima, Naoki, Fujimoto, Masanobu, Namba, Noriyuki, Kanzaki, Susumu
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society for Pediatric Endocrinology 2022
• Subjects: GH therapy; insulin-like growth factor 1 (IGF1); Insulin-like growth factor 1 receptor (IGF1R); Original; short stature; GH therapy; short stature; Insulin-like growth factor 1 receptor (IGF1R); insulin-like growth factor 1 (IGF1)
• ISSN: 0918-5739; 1347-7358
• DOI: 10.1297/cpe.2021-0064

Type 1 insulin-like growth factor receptor (IGF1R) plays an important role in normal fetal and postnatal growth. Over 30 pathogenic variants of IGF1R have been identified in patients with short stature. Yet, 20 years after the first report, a variety of phenotypes remain poorly defined. We analyzed the genetic and clinical data and responses to GH therapy in 11 patients using results from questionnaires. Eight of the 11 patients have already been reported in previous articles, and all of the identified mutations were heterozygous. The patients exhibited various phenotypes. At least two patients did not meet the criteria for GH treatment for small for gestational age (SGA) short stature, and two more patients showed lower serum IGF1 levels. Nine of the 11 patients had thin upper lips. Five patients with heterozygous IGF1R treated with GH exhibited similar height gains to those reported in previous Japanese studies on SGA short stature, which also led to extremely high serum IGF1 levels. Patients with short stature due to IGF1R mutations exhibit various phenotypes. Their presentation at diagnosis may be indistinguishable from common short stature. More specific clinical scoring that considers elevated IGF1 levels after GH treatment is needed to better detect IGF1R mutations.